Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Ocugen
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
July 29, 2026
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
July 28, 2026
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
July 13, 2026
Ocugen to Participate in Upcoming July Industry Conferences
July 1, 2026
Ocugen to Participate in Upcoming June Investor and Industry Conferences
June 2, 2026
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
May 14, 2026
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
May 13, 2026
Ocugen Provides Business Update with First Quarter 2026 Financial Results
May 5, 2026
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
May 5, 2026
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
May 4, 2026
1
2
Next Page
→